VCNX — VACCINEX, INC.
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1205922 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2024 | 213,000 | — | -3,387,000 | -3,374,000 | 2,596,000 | 1,107,000 | 5,084,000 |
| Sep 2024 | 52,000 | — | -4,552,000 | -5,732,000 | 4,854,000 | 2,906,000 | 6,175,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-3,932,000
Investing CF
$0
Financing CF
$2,133,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-358,561,000
Inventory
—
Receivables
$838,000
ST Investments
—
EBIT TTM
$-3,372,000
Pretax Income TTM
$-3,374,000
Interest Exp TTM
$2,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$601,000
EBITDA
$-18,641,000
Free Cash Flow
$-11,543,625
Enterprise Value
$3,393,468
Total Cash
$1,107,000
Total Debt
$25,000
Shares Out
2,676,637
Trailing EPS
$-8.88
Book Value
$-1.55
ROE
—
ROA
-376.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2024 | 601,000 | -18,735,000 | -18,634,000 | 2,596,000 | 5,084,000 | -2,488,000 | -16,186,000 |
| Dec 2023 | 570,000 | -22,885,000 | -20,251,000 | 3,631,000 | 5,942,000 | -2,311,000 | -21,379,000 |
| Dec 2022 | 275,000 | -19,906,000 | -19,815,000 | 7,977,000 | 2,784,000 | 5,193,000 | -19,074,000 |
| Dec 2021 | 900,000 | -22,490,000 | -22,380,000 | 9,843,000 | 2,431,000 | 7,412,000 | -25,298,000 |
TTM Snapshot
Revenues TTM
$601,000
NetIncome TTM
$-18,634,000
OpCashFlow TTM
—
Assets (Latest)
$4,854,000
Forward EPS
$-0.14
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.05T | $1179.27 | — |
| JNJ | JOHNSON & JOHNSON | $630.04B | $261.44 | — |
| ABBV | AbbVie Inc. | $488.55B | $276.47 | — |
| MRK | Merck & Co., Inc. | $359.22B | $145.60 | — |
| NVS | NOVARTIS AG | $273.23B | $143.75 | — |
News headlines (Yahoo Finance, 1h cache)
SEMA4D Blockade Reshapes the Tumor Immune Environment in Neoadjuvant Melanoma Study
2026-10-07 12:30 · Yahoo
Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer’s Association International Conference in London on July 13, 2026
2026-07-08 12:30 · Yahoo
Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease
2025-12-23 13:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.